Table 3.
Pathological subtype performance of RASSF1A, SHOX2 methylation, EGFR mutation, and combined assay panels using FFPE samples from patients with suspected malignant lung nodules
| Methylation positivity (%) | Pathological subtypes | Total | P for chi-square | P for linear correlation | ||
|---|---|---|---|---|---|---|
| Group 1 (AAH + AIS) | Group 2A (MIA) | Group 2B (IA) | ||||
| N | 125 | 59 | 74 | 258 | ||
| RASSF1A | 20a (16.0) | 24b (40.7) | 35b (47.3) | 79 (30.6) | < 0.001 | < 0.001 |
| SHOX2 + | 15a (12.0) | 14a, b (23.7) | 32b (43.2) | 61 (23.6) | < 0.001 | < 0.001 |
| TM + | 28a (22.4) | 30b (50.8) | 49b (66.2) | 107 (41.5) | < 0.001 | < 0.001 |
| EGFR + | 34a (34.0) | 25a, b (25.0) | 41b (41.0) | 100 (38.9) | < 0.001 | < 0.001 |
| RASSF1A + EGFR + | 40a (32.0) | 38b (64.4) | 58b (78.4) | 136 (52.7) | < 0.001 | < 0.001 |
| SHOX2 + EGFR + | 43a (34.4) | 33b (55.9) | 59c (79.7) | 135 (52.3) | < 0.001 | < 0.001 |
| TM + EGFR + | 48a (38.4) | 41b (69.5) | 66c (89.2) | 155 (60.1) | < 0.001 | < 0.001 |
TM + total methylation, which refers to the combined methylation detection of both the RASSF1A and SHOX2 genes
Each subscript letter denotes a subset of pathological subtype categories whose column proportions do not differ significantly from each other at the 0.05 level. The same subscript letters represent no statistically significant difference at the 0.05 level